Correlated increase of omentin-1 and adiponectin by exenatide, avandamet and dietary change in diet-induced obese rats.
Adipokines omentin-1 and adiponectin have been reported to improve insulin resistance. It is known that insulin sensitizers exenatide, avandamet, or diet change from high-fat to normal chow ameliorate metabolic disorders. However, whether these treatments increase omentin-1 levels in high fat-diet animals and the relationship between omentin- 1 and adiponectin remain largely unknown. We investigated the effect of insulin sensitizers exenatide and avandamet, and of dietary change on these adipokine levels, body weight, and insulin sensitivity in diet-induced obese rats. Obesity was induced in rats by high-fat diet feeding for 8 weeks, and then the rats were given exenatide, avandamet and diet change to normal chow, respectively, for additional 8 weeks. Compared to the high-fat control group, exenatide and avandamet treatment significantly induced adipose gene expression and elevated the circulation levels of omentin-1 and adiponectin, whereas they decreased the leptin gene expression and circulation level, which is associated with improvement of systemic insulin sensitivity and the glucose and lipid profile. Notably, there was a significant positive correlation between omentin-1 and adiponectin in the above regimens, suggesting that omentin-1 and adiponectin may contribute to the insulin-sensitizing effect of exenatide and avandamet.
Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing Medical University, Nanjing, China.
W-H
WH
Feng
Department of Endocrinology, Nanjing Children's Hospital Affiliated to Nanjing Medical University, Nanjing, China.
X-W
XW
Yuan
Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing Medical University, Nanjing, China.
G-Y
GY
Tong
Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing Medical University, Nanjing, China.
W-M
WM
Wang
Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing Medical University, Nanjing, China.
Y
Y
Hu
Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing Medical University, Nanjing, China.
S-M
SM
Shen
Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing Medical University, Nanjing, China.
P
P
Li
Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing Medical University, Nanjing, China.
Y
Y
Bi
Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing Medical University, Nanjing, China.
J
J
Hu
Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing Medical University, Nanjing, China.
L-L
LL
Shao
Medical School of Southeast University, Nanjing, China.
Y-Y
YY
Dai
Medical School of Southeast University, Nanjing, China.
Y-Q
YQ
Liu
Department of Endocrinology, Changzhou First People's Hospital, Nanjing, China.
S-K
SK
Xiang
Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing Medical University, Nanjing, China.
D-H
DH
Yang
Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing Medical University, Nanjing, China.
D-L
DL
Zhu
D052242:Adiponectin / Q000378:metabolism*; D000818:Animals; D016207:Cytokines / Q000378:metabolism*; D004338:Drug Combinations; D000077270:Exenatide; D008687:Metformin / Q000494:pharmacology*; D009765:Obesity / Q000209:etiology / Q000378:metabolism*; D010455:Peptides / Q000494:pharmacology*; D051381:Rats; D013844:Thiazoles / Q000494:pharmacology*; D014688:Venoms / Q000494:pharmacology*
D052242:Adiponectin; D016207:Cytokines; D004338:Drug Combinations; D010455:Peptides; D013844:Thiazoles; D014688:Venoms; C471074:rosiglitazone-metformin combination; D008687:Metformin; D000077270:Exenatide